Loading...
Proton-pump inhibitors (PPIs) block the secretion of gastric acid from parietal cells. As a result, serum gastrin levels rise and parietal-cell mass increases. When PPI therapy is discontinued, acid production rebounds.
To clarify the clinical significance of this rebound, investigators in Denmark randomized 120 healthy volunteers without gastrointestinal symptoms to receive either 12 weeks of placebo (control group) or 8 weeks of esomeprazole (40 mg/day) followed by 4 weeks of placebo (PPI group). Each week, participants completed the Gastrointestinal Symptom Rating Scale (GSRS) survey.
The two groups had similar baseline GSRS scores. At weeks 10, 11, and 12, the mean scores on acid-related symptoms were significantly higher in the PPI group…